International Series
Peptides aren't a North American phenomenon. K-beauty built a $10B industry around collagen science. European pharmacy culture put precision peptides behind the counter decades before the US biohacking world discovered them. This series covers what's happening worldwide — and what it means for your practice.
The same molecule. Radically different cultures built around it.
In Korea, peptide science evolved through the skincare industry — where consumer demand for proven ingredients, a rigorous regulatory environment, and fierce brand competition drove decades of dermatological R&D. GHK-Cu, copper peptides, oligopeptides — these aren't fringe biohacking topics in Seoul. They're shelf staples.
In France and Switzerland, peptides arrived through the pharmacy window. European doctors and pharmacists adopted bioregulatory peptides — many developed in Eastern Europe — as precision tools long before injectable peptides found a wellness audience in the US. The clinical culture is different: less DIY, more practitioner-led.
In Silicon Valley, the conversation is about optimization at scale. Longevity labs, quantified self, GLP-1 stacks for performance instead of obesity. The ethos is biohacking — experimental, fast-moving, sometimes reckless.
What connects these threads is the same underlying biology: peptides as signaling molecules with specificity and safety profiles that broad pharmaceuticals can't match. The cultures built around them reveal which problems a society has decided to prioritize.
Series Articles
Each piece in this series examines a distinct peptide culture — how it developed, what the evidence base looks like, and what practitioners and consumers in that market know that the global conversation is missing.
Korea built the world's most rigorous mass-market peptide skincare industry. The K-beauty pipeline — from ingredient approval to formulation to global distribution — is a case study in how consumer demand and strong regulatory frameworks can accelerate science. We break down what the dermatological evidence actually shows, which peptide categories dominate Korean formulations, and what the global skincare industry learned from Seoul.
France's pharmacy-first culture and Switzerland's precision medicine tradition shaped a very different relationship with bioregulatory peptides. Where US consumers biohack, European practitioners prescribe. We examine the clinical protocols in use, the regulatory frameworks governing peptide access, and why the French pharmacy model may represent the most patient-safe approach to peptide therapy worldwide.
BPC-157 is unscheduled research material in the US, Schedule 4 in Australia, pharmacy-only in some EU countries, and freely sold in others. The regulatory map for peptides is fragmented, evolving, and tells a story about how different health systems evaluate risk vs. evidence. This piece maps the current landscape and what it means for consumers and practitioners navigating sourcing and legality.
The US peptide scene is shaped by three forces: longevity venture capital (Altos, Unity, NewLimit), the biohacking community's appetite for self-experimentation, and a compounding pharmacy network that keeps supply flowing despite regulatory grey areas. We examine the performance peptide stack culture emerging from Silicon Valley, the clinical infrastructure being built around it, and whether the science is keeping up with the hype.
Series Status
Four regions, four distinct peptide cultures. One ongoing series examining the global wellness movement through a science-first lens.
Stay Ahead
The French & Swiss pharmacy piece, the regulatory landscape, and Silicon Valley coverage are in progress. Get notified when each drops — no noise, no spam.
🔒 One email when each piece drops. Unsubscribe anytime.